Clinical trials
Thyroid Eye Disease clinical trials
Below are recruiting thyroid eye disease clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07404111RecruitingPhase 1/Phase 2
Study of VV-14305 for thyroid eye disease
This study tests an investigational medication for thyroid eye disease, which causes bulging eyes and discomfort. The treatment is given as an injection near the eye, and the study will last about 12 months to see how safe and effective it is.
Livonia, MichiganAges 18–80 - NCT07265258RecruitingPhase 4
Teprotumumab for active thyroid eye disease
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07753603RecruitingPhase 3
Linsitinib for active moderate to severe thyroid eye disease
This study tests an experimental pill (linsitinib) for people with active thyroid eye disease. Participation may help reduce eye bulging and other symptoms, especially if other treatments haven't worked.
Las Vegas, NevadaAges 18 years+ - NCT07438405RecruitingPhase 2
Long-term safety study of AMG 732 for thyroid eye disease
This trial tests the long-term safety and effectiveness of AMG 732 for people with moderate-to-severe thyroid eye disease who have already completed an Amgen study of this drug. It allows continued treatment without needing immediate eye surgery.
Little Rock, ArkansasAges 18–99 - NCT07716397Recruiting
MRI study for thyroid eye disease diagnosis and care
This study uses MRI scans of the eye area to better understand and classify thyroid eye disease (TED). It aims to help doctors predict outcomes and personalize treatment. You may be eligible if you have stable TED or are a healthy volunteer.
Shanghai, Huangpu DistrictAges 18–75 - NCT07622368RecruitingPhase 1
Testing IBI3031 for Active Thyroid Eye Disease
This early-stage trial tests a new drug called IBI3031 to treat active thyroid eye disease (TED), a condition where the immune system attacks muscles and tissue around the eyes, causing swelling, bulging, and sometimes double vision. The study aims to see if this drug can reduce inflammation and improve symptoms.
Shenyang, LiaoningAges 18–75 - NCT04673643RecruitingPhase 2
Nerve stimulation for dry eye symptoms
This Phase 2 study tests a device that delivers gentle stimulation to a nerve near the ear to help improve dry eye disease. It may help reduce dryness and discomfort, if you meet the study’s health and safety requirements.
BeijingAges 18–65 - NCT04936854RecruitingPhase 2
Sirolimus or steroid drops for active Graves eye disease
This Phase 2 study compares sirolimus versus corticosteroids to treat active thyroid eye disease. It aims to see which treatment works better to calm eye inflammation and improve symptoms, without needing urgent eye surgery.
Bergen, HordalandAges 18–80 - NCT06112340RecruitingPhase 2/Phase 3
Extension study of linsitinib for thyroid eye disease
This trial tests two doses of an oral medication (linsitinib) for people with active, moderate-to-severe thyroid eye disease who were in a previous study and didn't improve enough or had their bulging come back. It aims to see if continuing treatment can help with eye bulging and other symptoms.
Miami, FloridaAges 18 years+ - NCT06275373Recruiting
Teprotumumab for thyroid eye disease study
This study tests if the drug teprotumumab can help with symptoms of thyroid eye disease, such as bulging eyes, pain, or double vision. It is for adults who are beneficiaries of the Department of Defense (DOD).
Bethesda, MarylandAges 18 years+ - NCT06359795Recruiting
PET Scan for Thyroid Eye Disease Activity
This study uses a special PET/CT scan (with a tracer called 18F-AlF-FAPI) to see how active your thyroid eye disease is. It may help doctors better understand and manage the condition.
Beijing, Beijing MunicipalityAges 18–80 - NCT06569758RecruitingPhase 1
A study of GenSci098 for active thyroid eye disease
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06989918RecruitingPhase 3
Study of MHB018A for active thyroid eye disease
This trial tests a new medicine called MHB018A for people with active, moderate to severe thyroid eye disease. It aims to see if the drug can reduce eye symptoms like bulging and inflammation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07113262RecruitingPhase 3
Study of IBI311 for people with inactive thyroid eye disease
This trial tests a new medication called IBI311 for people whose thyroid eye disease is no longer active but still causes bulging eyes. It aims to see if the drug can reduce eye bulging safely.
Shenyang, LiaoningAges 18–80 - NCT07211776RecruitingPhase 3
Study of ZL-1109 for active thyroid eye disease
This trial tests a new drug called ZL-1109 for people with active, moderate to severe thyroid eye disease (TED). It aims to see if the drug can reduce symptoms like bulging eyes and help patients feel better without using steroids.
BeijingAges 18–75 - NCT07257185RecruitingPhase 3
MHB018A for Chronic Thyroid Eye Disease
This study tests a new medication called MHB018A for people with chronic Thyroid Eye Disease (TED) that is moderate to severe. It aims to see if the drug can help improve symptoms and quality of life over time.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07262476RecruitingPhase 3
Extension study of MHB018A for thyroid eye disease
This study tests a longer-term use of MHB018A for people with thyroid eye disease who did not fully respond to treatment in a previous study. It aims to see if further treatment can help improve eye bulging and other symptoms.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07400757Recruiting
Statin and vitamin D for active thyroid eye disease
This trial tests whether a statin (a cholesterol-lowering medicine) combined with vitamin D can improve active thyroid eye disease. It may help if you have both eye inflammation and high cholesterol.
Taipei, TaiwanAges 20 years+ - NCT07423013Recruiting
Teprotumumab treatment for active thyroid eye disease
This trial tests a new version of an antibody treatment (teprotumumab) for people with active thyroid eye disease. It aims to reduce bulging and inflammation of the eyes, and you must have had symptoms for less than 9 months to join.
BeijingAges 18–80 - NCT07547930RecruitingPhase 2
Tofacitinib for Steroid-Resistant Thyroid Eye Disease
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
Xiamen, FujianAges 18–75 - NCT07597200RecruitingPhase 1
Cizutamig treatment for active thyroid eye disease
This study tests a new drug called cizutamig for thyroid eye disease (TED), a condition where the eye muscles and tissues swell due to Graves' disease. The drug is designed to reduce inflammation and may help improve symptoms like eye bulging, double vision, and discomfort.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05012033Recruiting
Study how high-dose steroids move through the body
This study measures blood levels of high-dose steroid medicines (prednisolone or related steroids) to understand how the body processes them in different real-life situations. It may help improve how steroids are dosed and monitored for people needing short-term or longer-term anti-inflammatory treatment.
LondonAges 18–75 - NCT07229001Enrolling by invitation
Treating Severe MGD in Children and Teens
This trial studies a treatment for severe Meibomian Gland Disease (MGD) in children and teens. MGD affects the tiny oil glands in your eyelids, which can cause dry, irritated eyes. The goal is to find a safe and effective way to help young patients with this condition.
Chicago, IllinoisAges 6–18 - NCT07453212Enrolling by invitation
Food supplement for dry eye caused by meibomian gland issues
This trial tests a food supplement designed to improve dry eye symptoms by targeting the microbiome. It may help if you have dry eye due to meibomian gland problems and are not using contact lenses or certain other eye treatments.
IstanbulAges 18–65
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Thyroid Eye Disease trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for thyroid eye disease?
- Yes. Clin2 currently lists 32 recruiting thyroid eye disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a thyroid eye disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a thyroid eye disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.